Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

405 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Retraction notice to: PS124-Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (PSC) in Individuals with Inflammatory Bowel Disease [J Hepatol 64 (2016) S199].
Eksteen B, Heatherington J, Oshiomogo J, Panaccione R, Kaplan G, Ghosh S. Eksteen B, et al. J Hepatol. 2017 Jan;66(1):254. doi: 10.1016/j.jhep.2016.10.020. Epub 2016 Dec 15. J Hepatol. 2017. PMID: 28042931 No abstract available.
Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus.
Ananthakrishnan AN, Kaplan GG, Bernstein CN, Burke KE, Lochhead PJ, Sasson AN, Agrawal M, Tiong JHT, Steinberg J, Kruis W, Steinwurz F, Ahuja V, Ng SC, Rubin DT, Colombel JF, Gearry R; International Organization for Study of Inflammatory Bowel Diseases. Ananthakrishnan AN, et al. Among authors: kaplan gg. Lancet Gastroenterol Hepatol. 2022 Jul;7(7):666-678. doi: 10.1016/S2468-1253(22)00021-8. Epub 2022 Apr 27. Lancet Gastroenterol Hepatol. 2022. PMID: 35487235 Review.
Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials.
Cholapranee A, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN. Cholapranee A, et al. Among authors: kaplan gg. Aliment Pharmacol Ther. 2017 May;45(10):1291-1302. doi: 10.1111/apt.14030. Epub 2017 Mar 22. Aliment Pharmacol Ther. 2017. PMID: 28326566 Free PMC article. Review.
Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.
Targownik LE, Benchimol EI, Bernstein CN, Singh H, Lix L, Tennakoon A, Leung S, Aviña A, Coward S, Jones J, Kaplan G, Murthy SK, Nguyen GC, Peña-Sánchez JN. Targownik LE, et al. Clin Gastroenterol Hepatol. 2019 Aug;17(9):1788-1798.e2. doi: 10.1016/j.cgh.2018.11.003. Epub 2018 Nov 15. Clin Gastroenterol Hepatol. 2019. PMID: 30448599
405 results